Pacer Advisors
RPRX icon

Pacer Advisors’s Royalty Pharma RPRX Stock Holding History

Pacer Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-689,194
Closed -$33.1M – 2614
2026
Q1 		$33.1M Sell
689,194
-64,855
-9% -$2.84M 0.09% 229
2025
Q4 		$29.1M Buy
754,049
+192,463
+34% +$7.34M 0.07% 249
2025
Q3 		$19.8M Buy
+561,586
New +$20.3M 0.05% 321
2024
Q3 		– Sell
-36,353
Closed -$959K – 2675
2024
Q2 		$959K Buy
36,353
+13,538
+59% +$375K ﹤0.01% 1333
2024
Q1 		$693K Buy
22,815
+14,578
+177% +$430K ﹤0.01% 1410
2023
Q4 		$231K Buy
8,237
+4,177
+103% +$115K ﹤0.01% 1856
2023
Q3 		$110K Buy
+4,060
New +$121K ﹤0.01% 2140

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pacer Advisors's RPRX Position: Q2 2026 in Review

Pacer Advisors sold out of Royalty Pharma (RPRX) in Q2 2026, closing a stake of 689,194 shares — an estimated $33.1M sold.

Pacer Advisors first reported a position in RPRX in Q3 2023 and held it in 7 quarters. The position peaked at $33.1M in Q1 2026. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Pacer Advisors reported no remaining Royalty Pharma position as of Q2 2026 after selling out during the quarter.
  • Pacer Advisors sold 689,194 Royalty Pharma shares in Q2 2026, an estimated $33.1M.
  • Pacer Advisors first reported a position in Royalty Pharma in Q3 2023 and held it in 7 quarters.
  • Pacer Advisors's Royalty Pharma position peaked at $33.1M in Q1 2026.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.